

# Daniel Shepshelovich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6771959/publications.pdf>

Version: 2024-02-01

87  
papers

1,102  
citations

471509

17  
h-index

477307

29  
g-index

90  
all docs

90  
docs citations

90  
times ranked

1663  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 677-690.	1.9	189
2	Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1594-1607.	1.1	81
3	Medication-induced SIADH: distribution and characterization according to medication class. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1801-1807.	2.4	67
4	Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. <i>Lupus</i> , 2006, 15, 183-190.	1.6	55
5	Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 531-545.	2.5	42
6	The syndrome of inappropriate antidiuretic hormone secretion: Distribution and characterization according to etiologies. <i>European Journal of Internal Medicine</i> , 2015, 26, 819-824.	2.2	36
7	Colorectal cancer in young patients: is it a distinct clinical entity?. <i>International Journal of Clinical Oncology</i> , 2016, 21, 684-695.	2.2	35
8	Post renal transplant anemia: severity, causes and their association with graft and patient survival. <i>BMC Nephrology</i> , 2019, 20, 51.	1.8	32
9	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1798-1804.	1.6	27
10	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 980-988.	6.3	25
11	Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. <i>Hematological Oncology</i> , 2020, 38, 584-588.	1.7	24
12	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019, 24, e146-e148.	3.7	23
13	The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. <i>Lung Cancer</i> , 2021, 152, 58-65.	2.0	22
14	Malignancy associated SIADH: Characterization and clinical implications. <i>Acta Oncologica</i> , 2016, 55, 1190-1195.	1.8	20
15	Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. <i>Cancer Medicine</i> , 2018, 7, 5478-5487.	2.8	19
16	BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 2433-2454.	1.8	19
17	Association Between Data Sources and US Food and Drug Administration Drug Safety Communications. <i>JAMA Internal Medicine</i> , 2019, 179, 1590.	5.1	18
18	Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant Bacteria. <i>Clinical Infectious Diseases</i> , 2021, 72, 1968-1974.	5.8	18

#	ARTICLE	IF	CITATIONS
19	Molecular-based diagnosis of <i>Clostridium difficile</i> infection is associated with reduced mortality. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1137-1142.	2.9	14
20	Reporting infections in clinical trials of patients with haematological malignancies. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1494-1500.	6.0	14
21	Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity. <i>World Journal of Gastroenterology</i> , 2017, 23, 1387.	3.3	14
22	Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration. <i>Annals of Internal Medicine</i> , 2020, 173, 445-449.	3.9	13
23	Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety Communications. <i>JAMA Internal Medicine</i> , 2020, 180, 1420.	5.1	13
24	Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. <i>Cancer Genetics</i> , 2015, 208, 575-579.	0.4	12
25	The safety of pulse corticosteroid therapy- Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 534-545.	3.4	12
26	Effect of Ticagrelor on Reducing the Risk of Gram-Positive Infections in Patients With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2020, 130, 56-63.	1.6	12
27	Emergency Use Authorizations of COVID-19-Related Medical Products. <i>JAMA Internal Medicine</i> , 2022, 182, 228.	5.1	12
28	MicroRNA signature is indicative of long term prognosis in diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2015, 39, 632-637.	0.8	11
29	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1228-1237.	2.5	11
30	Attention to age: similar dosing regimens lead to different vancomycin levels among older and younger patients. <i>Age and Ageing</i> , 2020, 49, 26-31.	1.6	11
31	Comparison of reporting phase III randomized controlled trials of antibiotic treatment for common bacterial infections in ClinicalTrials.gov and matched publications. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1211.e9-1211.e14.	6.0	10
32	Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database. <i>Investigational New Drugs</i> , 2018, 36, 933-938.	2.6	10
33	Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. <i>Mayo Clinic Proceedings</i> , 2019, 94, 74-83.	3.0	10
34	The clinical importance of early acute hepatic porphyria diagnosis: a national cohort. <i>Internal and Emergency Medicine</i> , 2021, 16, 133-139.	2.0	10
35	Cost Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the Gap. <i>Infectious Diseases and Therapy</i> , 2021, 10, 621-630.	4.0	10
36	Perception of prognosis of cancer patients by non-oncologists. <i>International Journal of Clinical Practice</i> , 2016, 70, 1027-1032.	1.7	9

#	ARTICLE	IF	CITATIONS
37	Screening for occult cancer in idiopathic venous thromboembolism " Systemic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2017, 42, 74-80.	2.2	9
38	Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications. <i>Investigational New Drugs</i> , 2017, 35, 827-833.	2.6	9
39	Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: A multinational survey. <i>Transplant Infectious Disease</i> , 2019, 21, e13134.	1.7	8
40	Yield of workup for patients with idiopathic presentation of the syndrome of inappropriate antidiuretic hormone secretion. <i>European Journal of Internal Medicine</i> , 2016, 32, 60-64.	2.2	7
41	Educational interventions encouraging appropriate use of blood transfusions. <i>Vox Sanguinis</i> , 2017, 112, 150-155.	1.5	7
42	Undisclosed Financial Conflicts of Interest of Authors of Clinical Drug Trials Published in Influential Medical Journals: A Cohort Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2272-2276.	3.0	7
43	Vaccine safety " is the SARS-CoV-2 vaccine any different?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1322-1325.	3.3	7
44	Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2415-2418.	3.0	7
45	Rapid "Zone Lung Ultrasound Protocol is Comparable to a Full 12"Zone Protocol for Outcome Prediction in Hospitalized <scp>COVID</scp>"19 Patients. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 1677-1687.	1.7	7
46	The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-9.	1.5	5
47	The association of vancomycin trough levels with outcomes among patients with methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections: Retrospective cohort study. <i>PLoS ONE</i> , 2019, 14, e0214309.	2.5	5
48	Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals. <i>European Journal of Internal Medicine</i> , 2020, 71, 45-49.	2.2	5
49	Hodgkin Lymphoma and Hypothermia: Case Report and Review of the Literature. <i>Acta Haematologica</i> , 2014, 131, 227-230.	1.4	4
50	High Lung Cancer Incidence in Heavy Smokers Following Hospitalization due to Pneumonia. <i>American Journal of Medicine</i> , 2016, 129, 332-338.	1.5	4
51	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	7.7	4
52	Effect of liver fibrosis on survival in patients with intrahepatic cholangiocarcinoma: a SEER population-based study. <i>Oncotarget</i> , 2020, 11, 4438-4447.	1.8	4
53	Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 685-691.	2.4	3
54	Endocrinopathy-induced euvolemic hyponatremia. <i>Internal and Emergency Medicine</i> , 2018, 13, 679-688.	2.0	3

#	ARTICLE	IF	CITATIONS
55	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102293.	7.7	3
56	Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. <i>Annals of Hematology</i> , 2021, 100, 2879-2887.	1.8	3
57	Absence of hemoglobin increase is associated with reduced graft survival after kidney transplantation. <i>Clinical Transplantation</i> , 2022, 36, e14602.	1.6	3
58	Risk Factors and Outcome of Polymicrobial Bacteremia: A Retrospective Cohort Study. <i>Israel Medical Association Journal</i> , 2020, 22, 279-284.	0.1	3
59	Chills During Hemodialysis: Prediction and Prevalence of Bacterial Infections – A Retrospective Cohort Study. <i>American Journal of Medicine</i> , 2017, 130, 477-481.	1.5	2
60	Agranulocytosis Associated with Waldenström Macroglobulinemia. <i>Acta Haematologica</i> , 2018, 140, 42-45.	1.4	2
61	Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual. <i>JAMA Oncology</i> , 2019, 5, 107.	7.1	2
62	Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies. <i>Acta Haematologica</i> , 2020, 143, 73-77.	1.4	2
63	Extended Follow-up of an Educational Intervention Encouraging Appropriate Use of Blood Transfusions. <i>Acta Haematologica</i> , 2020, 143, 446-451.	1.4	2
64	Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administration. <i>Leukemia and Lymphoma</i> , 2020, 61, 2216-2220.	1.3	2
65	Incidence of lung cancer following pneumonia in smokers: a population-based study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, , .	0.5	2
66	Mapping PRO-CTCAE responses to clinician-graded adverse events, dose reductions, interruptions, and discontinuations in phase I cancer trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2014-2014.	1.6	2
67	Searching for the leak. <i>American Journal of Hematology</i> , 2014, 89, 928-930.	4.1	1
68	The effects of erythropoietin signaling on telomerase regulation in non-erythroid malignant and non-malignant cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 274-282.	2.1	1
69	Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?. <i>Oncotarget</i> , 2018, 9, 30942-30943.	1.8	1
70	Association of two <i>BRM</i> promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. <i>Molecular Carcinogenesis</i> , 2019, 58, 1960-1973.	2.7	1
71	Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus. <i>Rheumatology</i> , 2021, , .	1.9	1
72	Reporting of patient reported outcome (PRO) in clinical trials: A systematic review of clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6590-6590.	1.6	1

#	ARTICLE	IF	CITATIONS
73	BRCA1 and telomere dysfunction-implications for malignant transformation.. Journal of Clinical Oncology, 2015, 33, e12512-e12512.	1.6	1
74	The association between treatment for metabolic disorders and breast cancer characteristics.. Journal of Clinical Oncology, 2016, 34, 527-527.	1.6	1
75	Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All. Journal of Thoracic Oncology, 2018, 13, 601-602.	1.1	0
76	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. Cancer Chemotherapy and Pharmacology, 2020, 85, 469-472.	2.3	0
77	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, 1086-1086.	1.6	0
78	Patient experience of early high grade symptomatic adverse events on early phase clinical trials using the PRO-CTCAE.. Journal of Clinical Oncology, 2021, 39, 12051-12051.	1.6	0
79	Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.. Journal of Clinical Oncology, 2021, 39, 6571-6571.	1.6	0
80	Colorectal cancer in young patients: Is it a distinct clinical entity?. Journal of Clinical Oncology, 2015, 33, e14594-e14594.	1.6	0
81	The association between antihypertensive medications and breast cancer characteristics.. Journal of Clinical Oncology, 2016, 34, e12000-e12000.	1.6	0
82	Malignancy associated SIADH: Characterization and clinical implications.. Journal of Clinical Oncology, 2016, 34, e21622-e21622.	1.6	0
83	Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity.. Journal of Clinical Oncology, 2017, 35, 552-552.	1.6	0
84	The Association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AG1G CO.20 trial analysis.. Journal of Clinical Oncology, 2018, 36, 633-633.	1.6	0
85	Post-marketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials.. Journal of Clinical Oncology, 2018, 36, e18717-e18717.	1.6	0
86	De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2019, 37, 524-524.	1.6	0
87	Does ethnicity affect the relationship between body mass index (BMI) and overall survival (OS) in non-small cell lung cancer (NSCLC)? A pooled analysis of 17,326 International Lung Cancer Consortium (ILCCO) patients (pts).. Journal of Clinical Oncology, 2019, 37, 1562-1562.	1.6	0